Amanda Wooding
Deputy Head of Life Sciences @ University of Cambridge Enterprise
Cambridge, United Kingdom
Amanda Wooding is a funding round investor at University of Cambridge Enterprise in Cambridge focused on Health Care and Medical. Amanda joined Cambridge Enterprise in January 2009 as a Technology Manager in the Life Sciences Team. Before joining Cambridge Enterprise she gained over ten years of experience in technology commercialisation from roles within The Wellcome Trust commercialisation company Catalyst Biomedica and Acambis. As the UK based Director of BusinessDevelopment at Acambis she was responsible for in and out licensing, most notably securing a Phase III outlicensing deal with Sanofi Pasteur. Amanda has a PhD in molecular endocrinology from the University of Cambridge and enjoyed post doctoral research positions both at Cambridge and in industry.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Amanda Wooding invests in
Stages Amanda Wooding invests in
Countries Amanda Wooding invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (67%)
- Medical 1 (33%)
- Artificial Intelligence 1 (33%)
Stage
- Funding Round 2 (67%)
- Seed 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
52 North Health
|
52 North Health aims to improve healthcare with a medical device that uses artificial intelligence (AI) to determine the risk of neutropenic sepsis for patients undergoing chemotherapy. | $6M / Dec 03, 2024 | |
Kalium Health
|
Kalium Health are pioneering patient-centric approaches to help with the management of kidney disease - a growing problem costing US Medicare alone $2B every week. Value-based kidney care providers are seizing the initiative and capturing market share in the US, and now need advanced tools and data to drive cost-effective improvements in care.Thefirst product that Kalium Health is developing is their blood potassium self-test that addresses a key risk, and huge treatment cost, in kidney disease. The team have developed proven blood sensing technology and have a clear regulatory pathway and targeted go-to-market strategy. Their ultimate vision is to transform the standard of care for millions of patients. | Nov 09, 2022 | |
|
Kalium Health
|
Kalium Health are pioneering patient-centric approaches to help with the management of kidney disease - a growing problem costing US Medicare alone $2B every week. Value-based kidney care providers are seizing the initiative and capturing market share in the US, and now need advanced tools and data to drive cost-effective improvements in care.Thefirst product that Kalium Health is developing is their blood potassium self-test that addresses a key risk, and huge treatment cost, in kidney disease. The team have developed proven blood sensing technology and have a clear regulatory pathway and targeted go-to-market strategy. Their ultimate vision is to transform the standard of care for millions of patients. | $1.5M / Seed / Nov 09, 2022 |
Co-Investors
University of Cambridge Enterprise, also known as Cambridge Enterprise Seed Funds, consisting of the Challenge Fund and the Venture Fund, is a resource for members of the University of Cambridge and the Babraham Institute. Investments are priced and structured competitively with other sources of early stage seed capital in order to encourageco-investment, follow-on funding and commercialisation of University of Cambridge and Babraham Institute inventions.
University of Cambridge Enterprise Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Amanda Wooding
Deputy Head of Life Sciences
|
|||
Anne Dobrée
Head of Seed Funds
|
|||
Christian Pratt
Head of Marketing and Communications
|
|||
Emma Barker
Senior Commercialisation Associate
|
|||
Georgina Weller
Office Manager
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Amanda Wooding invest in?
Amanda Wooding invests primarily in Health Care, Medical and Artificial Intelligence startups, most often at Funding Round and Seed stage. Most of the 3 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Amanda Wooding?
Public channels for Amanda Wooding include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Amanda Wooding last invest?
The most recent investment recorded for Amanda Wooding closed in Dec 2024. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
